Endothelial reactive oxygen-forming NADPH oxidase 5 is a possible player in diabetic aortic aneurysm but not atherosclerosis

Florence Ho1,6, Anna M. D. Watson1,2,6, Mahmoud H. Elbatreek3,4,6,*, Pamela W. M. Kleikers4, Waheed Khan1, Karly C. Sourris3, Aozhi Dai1, Jay Jha1, Harald H. H. W. Schmidt4,6 & Karin A. M. Jandeleit-Dahm1,5,6

Atherosclerosis and its complications are major causes of cardiovascular morbidity and death. Apart from risk factors such as hypercholesterolemia and inflammation, the causal molecular mechanisms are unknown. One proposed causal mechanism involves elevated levels of reactive oxygen species (ROS). Indeed, early expression of the ROS forming NADPH oxidase type 5 (Nox5) in vascular endothelial cells correlates with atherosclerosis and aortic aneurysm. Here we test the proatherogenic Nox5 hypothesis using mouse models. Because Nox5 is missing from the mouse genome, a knock-in mouse model expressing human Nox5 in its physiological location of endothelial cells (eNox5ki/ki) was tested as a possible new humanised mouse atherosclerosis model. However, whether just on a high cholesterol diet or by crossing in aortic atherosclerosis-prone ApoE−/− mice with and without induction of diabetes, Nox5 neither induced on its own nor aggravated aortic atherosclerosis. Surprisingly, however, diabetic ApoE−/− x eNox5ki/ki mice developed aortic aneurysms more than twice as often correlating with lower vascular collagens, as assessed by trichrome staining, without changes in inflammatory gene expression, suggesting that endothelial Nox5 directly affects extracellular matrix remodelling associated with aneurysm formation in diabetes. Thus Nox5-derived reactive oxygen species are not a new independent mechanism of atherosclerosis but may enhance the frequency of abdominal aortic aneurysms in the context of diabetes. Together with similar clinical findings, our preclinical target validation opens up a first-in-class mechanism-based approach to treat or even prevent abdominal aortic aneurysms.

Atherosclerosis with and without diabetes are a major cause of cardiovascular morbidity and death. Consequences include ischemic stroke, myocardial infarction, aortic aneurysm, and death. Despite the progress made in prevention and treatment of atherosclerosis, this disease and its consequences have grown globally and are the primary cause of deaths around the world. Apart from elevated LDL cholesterol and a proinflammatory state, the causal pathomechanisms leading to atherosclerosis and allowing a curative therapy are not fully understood. One mechanism that has been suggested for decades to be causal in atherogenesis is dysregulated reactive oxygen species (ROS) formation. ROS-scavenging antioxidants are, however, not effective, or beneficial overall, possibly due to also many protective effects of ROS and antioxidants interfering at the same time with protective

---

1Department of Diabetes, Central Clinical School, Monash University, 99 Commercial Road, Melbourne, VIC 3004, Australia. 2Atherothrombosis and Vascular Biology Laboratory, Baker Heart and Diabetes Institute, 75 commercial Road, Melbourne, VIC 3004, Australia. 3Department of Pharmacology and Toxicology, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt. 4Department of Pharmacology and Personalised Medicine, MeHNS, Faculty of Health, Medicine & Life Science, Maastricht University, Universiteitssingel 40, 6229 ER Maastricht, The Netherlands. 5Institute for Clinical Diabetology, German Diabetes Centre, Leibniz Centre for Diabetes Research at Heinrich Heine University Düsseldorf, Auf’m Hennekamp 65, 40225 Düsseldorf, Germany. 6These authors contributed equally: Florence Ho, Anna M. D. Watson and Mahmoud H. Elbatreek. *email: melbatreek@ppmlab.net; hschmidt@ppmlab.net; karin.jandeleit-dahm@monash.edu
Nox5 in diabetic complications and because atherosclerosis is accelerated in diabetes, we further induced aneurysm and Nox5 appear to stand out in atherosclerosis, at least by the clinical correlation of its expression with and without diabetes. Indeed, diabetic ApoE−/− x eNOX5ki/ki mice formed more aneurysms than ApoE−/− WT mice (Table 3, Fig. 3). According to the Daugherty classification, the disease-triggering enzymatic sources of ROS and leave beneficial enzymatic sources of ROS untouched. Instead, an alternative approach that has been put forward is to identify and inhibit the disease-triggering enzymatic sources of ROS and leave beneficial enzymatic sources of ROS untouched.

The only known dedicated enzymatic source of ROS is NADPH oxidase with five isozymes (Nox1-5). Nox1, at least preclinically plays only a minor role in both comorbidities; knocking out Nox2 even increases infections and mortality in diabetes and is thus not a viable target; Nox3 seems to be involved in pulmonary hypertension; Nox4 is, surprisingly, rather atheroprotective and downregulated in abdominal aortic aneurysm; Nox5 appear to stand out in atherosclerosis, at least by the clinical correlation of its expression levels in endothelial cells, both in early stages of coronary artery disease and aortic aneurysm. However, the functional validation of this possible role of NOX5 in atherosclerosis is missing, possibly due to the fact that the Nox5 gene is absent from the mouse and rat genome. To test this Nox5 hypothesis of atherosclerosis, we investigated humanized Nox5 knock-in (KI) mice expressing Nox5 in endothelial cells (eNOX5KIKI), i.e., the physiological location in humans.

**Results**

eNOX5 does not induce atherosclerosis per se. We first tested whether the knock-in of the Nox5 gene per se can induce atherosclerosis in aged mice exposed to a high cholesterol Paigen diet, which is atherogenic in other aged mouse models. After 28 weeks of diet, eNOX5KIKI mice had lower body weights compared to WT mice, whilst kidney, liver, and heart weights (Table 1) and blood glucose, serum triglycerides and cholesterol levels were similar (Table 1).

We then measured the atherosclerotic plaque area in the whole aorta of both WT and eNOX5KIKI mice by en-face analysis. However, there was no plaque formation in both groups (Fig. 1a). We then considered that Nox5 might be involved only in the early stages of atherosclerosis development, i.e., fatty streak formation at the aortic arch. To test this, we stained the aortic arch with a Haematoxylin and Eosin stain providing a comprehensive picture of the microanatomy. However, as before we did not detect any fatty streaks in WT and eNOX5KIKI mice (Fig. 1b). Also, aneurysms were not observed (not shown). These data indicated that endothelial expression of Nox5 per se is insufficient to develop fatty streaks, advanced atherosclerotic lesions, or aneurysms, even if mice are aged and exposed to an otherwise atherogenic diet. Thus, we next decided to retest the Nox5 hypothesis of atherosclerosis under conditions where atherosclerosis is observed and determine whether Nox5 KI aggravates this phenotype in the atherosclerosis prone apolipoprotein E (ApoE−/−) mouse in both normal and diabetic conditions.

eNOX5 does not aggravate atherosclerosis in ApoE−/− mice with and without diabetes. Mice deficient in apo E (ApoE−/− mice) spontaneously develop atherosclerosis and because atherosclerosis is accelerated in diabetes, we further induced diabetes in some of the eNOX5KIKI x ApoE−/− mice by the injection of low-dose streptozotocin (STZ). After 20 weeks, all diabetic mice (both WT and eNOX5KIKI) had lower body weights (Table 2), elevated glucose, HbA1c, total cholesterol and LDL levels, and similar blood pressure compared to their nondiabetic controls. There were no significant differences in all of the above-mentioned parameters between WT and eNOX5KIKI mice with or without diabetes, however, diabetic eNOX5KIKI mice had slightly higher body weights. These data show that endothelial expression of Nox5 has no effect on metabolic parameters and blood pressure in ApoE−/− mice with and without diabetes (Table 2).

When assessing the atherosclerotic plaque area in ApoE−/− x WT versus ApoE−/− x eNOX5KIKI mice with and without 20 weeks of diabetes, all diabetic mice showed a significant increase in atherosclerotic plaque area in total, arch, thoracic and abdominal aorta compared to non-diabetic mice, yet there was no difference between diabetic ApoE−/− x WT versus diabetic ApoE−/− x eNOX5KIKI mice in all areas (Fig. 2).

eNOX5 increases aneurysms in diabetic ApoE−/− mice. Finally, based on the clinical observations of Nox5 levels correlating with aortic aneurysms, we investigated whether Nox5 induces aortic aneurysm under atherosclerotic conditions with and without diabetes. Indeed, diabetic ApoE−/− x eNOX5KIKI mice formed more frequently aneurysms than ApoE−/− WT mice (Table 3, Fig. 3). According to the Daugherty classification, the

| Aged WT | Aged eNOX5KIKI |
|---------|---------------|
| Body weight, g | 40.5 ± 1.9 (19) | 35.8 ± 1.1 (16)* |
| Blood glucose, mmol/L | 5.0 ± 0.2 (19) | 4.6 ± 0.2 (17) |
| Cholesterol, mmol/L | 1.4 ± 0.1 (19) | 1.1 ± 0.1 (17) |
| Triglycerides, mmol/L | 0.13 ± 0.02 (19) | 0.15 ± 0.06 (17) |
| Kidney weight, g | 0.51 ± 0.03 (19) | 0.46 ± 0.02 (17) |
| Heart weight, g | 0.2 ± 0.005 (19) | 0.2 ± 0.008 (16) |
| Liver weight, g | 2.4 ± 0.2 (18) | 1.9 ± 0.1 (17) |

* compared with aged WT.

Table 1. Metabolic parameters in aged WT and eNOX5KIKI mice. Data are shown as mean ± SEM (n). P<0.05 compared with aged WT.
Figure 1. No plaques or fat infiltration in the aorta of the aged eNOX5\textsuperscript{ki/ki} mice. Representative images of aorta of aged WT and eNOX5\textsuperscript{ki/ki} mice stained with Sudan stain (a) and aortic arch stained with H/E stain (b). a. Absence of plaques or fat infiltration in the aorta of the aged WT and eNOX5\textsuperscript{ki/ki}. b. No fatty streaks or plaque formation were seen in the aortic arch of the aged WT and eNOX5\textsuperscript{ki/ki}. Plates are representative of n = 4–5 experiments. Bar indicates 2 mm (a) and 50 µm (b).

Table 2. Baseline data including metabolic parameters for animals at 20 weeks of study. Data shown as mean ± SEM. Two-way ANOVA statistics shown in columns. Post-hoc multiple comparisons test (Tukey’s): # versus Control ApoE\textsuperscript{−/−} x WT group; † versus Control ApoE\textsuperscript{−/−} x eNOX5\textsuperscript{ki/ki} group; ‡ versus Diabetic ApoE\textsuperscript{−/−} x WT group. n = 6–10/group for body weight, 24 h urine output and HbA1c values; n = 7–9/group for plasma values; n = 8–18/group for tibia lengths; n = 9–15 for blood pressure measurements. The first \( p \)-value “the effect of diabetes” is for the comparison between non-diabetic WT mice and diabetic WT mice. The second \( p \)-value “the effect of NOX5” is for the comparison between diabetic WT mice and diabetic NOX5 mice. ApoE\textsuperscript{−/−} = Apolipoprotein E knockout; HDL = high density lipoprotein; LDL = low density lipoprotein; NOX = NADPH oxidase. Significant values are bold.

|                          | Control ApoE\textsuperscript{−/−} x WT | Control ApoE\textsuperscript{−/−} x eNOX5\textsuperscript{ki/ki} | Diabetic ApoE\textsuperscript{−/−} x WT | Diabetic ApoE\textsuperscript{−/−} x eNOX5\textsuperscript{ki/ki} | \( p \)-value: Effect of diabetes | \( p \)-value: Effect of NOX5 |
|--------------------------|----------------------------------------|-------------------------------------------------|---------------------------------|-------------------------------------------------|-------------------------------|-------------------------------|
| Body weights (g)         | 30.6 ± 1.0                             | 31.6 ± 1.1                                       | 25.1 ± 0.3 #†                  | 28.8 ± 0.5 #†                                  | < 0.0001                      | 0.0110                        |
| 24 h urine output (mL)   | 1.0 ± 0.1                              | 0.9 ± 0.2                                         | 16.0 ± 1.6 #†                  | 16.8 ± 2.7 #†                                  | < 0.0001                      | 0.8490                        |
| HbA1c (mmol/mol, %)      | 4.6 ± 0.2                              | 4.4 ± 0.1                                         | 10.1 ± 0.6 #†                  | 9.6 ± 0.3 #†                                   | < 0.0001                      | 0.3560                        |
| Plasma glucose (mmol/L)  | 9.3 ± 0.8                              | 9.8 ± 0.7                                         | 21.6 ± 2.2 #†                  | 24.1 ± 2.8 #†                                  | < 0.0001                      | 0.3957                        |
| Cholesterol (mmol/L)     | 14.1 ± 0.5                             | 11.5 ± 0.3                                        | 23.7 ± 4.6 #†                  | 22.5 ± 1.7 #†                                  | < 0.0001                      | 0.3516                        |
| Triglycerides (mmol/L)   | 1.3 ± 0.1                              | 0.8 ± 0.1                                         | 1.6 ± 0.3                       | 1.3 ± 0.2 ‡                                     | 0.0947                        | 0.0448                        |
| Plasma HDL (mmol/L)      | 1.6 ± 0.0                              | 1.5 ± 0.1                                         | 1.0 ± 0.2 #†                   | 0.8 ± 0.2 #†                                   | < 0.0001                      | 0.3431                        |
| Plasma LDL (mmol/L)      | 9.9 ± 4.6                              | 12.0 ± 1.6                                        | 21.1 ± 0.5 #†                  | 22.1 ± 0.2 #†                                  | < 0.0001                      | 0.4616                        |
| Tibia lengths (mm)       | 17.2 ± 0.2                             | 17.6 ± 0.1                                        | 17.5 ± 0.1                      | 17.4 ± 0.1                                     | 0.8589                        | 0.4300                        |
| Systolic blood pressure (mmHg) | 105 ± 27                          | 105 ± 27                                          | 94 ± 30                         | 107 ± 36                                      | 0.3421                        | 0.1783                        |
aneurysms were type II^{25}. The combination of Nox5 expression and diabetes was associated with a significant increase in aneurysm incidence compared to non-diabetic Nox5 expressing mice (Table 3, \( p < 0.01 \)).

To explore the possible downstream mechanisms of this Nox5-dependent effect, we examined gene expression of inflammatory, oxidative/antioxidant and fibrotic markers in the aorta (Table 4). Diabetes induced an increase in the expression of monocyte chemoattractant protein-1 (MCP-1), the macrophage marker F4/80, nitrotyrosine, Nox2, heme oxygenase-1 (HO-1) and platelet derived growth factor (PDGF) (Table 4). Notably,
Figure 3. Whole mount examples of sudan IV stained aortas of diabetic ApoE<sup>−/−</sup> mice with and without endothelial NOX5 expression. Bars (white, at bottom left) indicate 1 mm.

Table 4. RT-PCR gene expression data for ApoE<sup>−/−</sup> x NOX5<sup>ki/ki</sup> animals and their respective WT controls at 10 weeks of study. Data shown as mean ± SEM, with all values expressed relative to non-diabetic NOX5 negative animals. Two-way ANOVA statistics shown in columns, in bold if \( p < 0.05 \). Post-hoc multiple comparisons test (Tukey’s): # versus Control ApoE<sup>−/−</sup> x WT group; † versus Control ApoE<sup>−/−</sup> x eNOX5<sup>ki/ki</sup> group; ‡ versus Diabetic ApoE<sup>−/−</sup> x WT group. n = 6–9/group (except n = 5 for the diabetic NOX5 negative group; for NRF2, n = 5 for the diabetic eNOX5<sup>ki/ki</sup> group for CTGF, n = 5 for diabetic NOX5 negative group for MMP9). The first \( p \) value "the effect of diabetes" is for the comparison between non-diabetic WT mice and diabetic WT mice. The second \( p \) value "the effect of NOX5" is for the comparison between diabetic WT mice and diabetic NOX5 mice.
there was a trend towards reduced Nox2 expression in the diabetic eNOX5ki/ki mice compared to WT mice, yet there was no significant difference between both groups. Further, immunohistochemistry showed higher VCAM-1, nitrotyrosine and MCP-1 in diabetic mice compared to non-diabetic mice (See Supplementary Fig. 1 online and Supplementary Fig. 2 online). Yet, there was no difference between WT versus eNOX5ki/ki mice with/without diabetes in all markers (Table 4, See Supplementary Fig. 1 online).

However, diabetic ApoE−/− x eNOX5ki/ki mice showed lower fibronectin gene expression compared to diabetic ApoE−/− x WT mice (Table 4). This, however, did not translate to the protein level, where fibronectin protein expression was not significantly different between diabetic eNOX5ki/ki ApoE−/− and WT ApoE−/− mice (See Supplementary Fig. 3 online), whereas collagen accumulation in the plaques and underlying vascular wall was significantly reduced in diabetic ApoE−/− x eNOX5ki/ki compared to diabetic ApoE−/−/WT mice. This suggests that in diabetic mice, eNOX5 induces aneurysm not via an inflammatory mechanism but altered extracellular matrix remodelling (Fig. 4).

Discussion. In search for a causal mechanism in atherosclerosis, the superoxide-forming Nox5 was such a highly promising candidate. It is overexpressed in the endothelium in early atherosclerotic lesions, in vascular smooth muscle cells in the advanced coronary lesions in patients with coronary artery disease, and in human abdominal aortic aneurysm. The calcium-dependent activation of Nox5 and ROS generation in endothelial cells has been addressed by previous studies. Besides, in our previous study, we investigated the eNox5ki/ki mouse model in acute model of ischemic stroke which is inherently characterized by excitotoxicity and increased calcium levels.

However, despite its attractiveness and considerable circumstantial clinical evidence, our data argue against a previously unrecognized direct causal or aggravating role of Nox5 in diet-related or ApoE−/− induced atherosclerosis. Thus, the eNOX5ki/ki mouse cannot be a humanized mechanism-based model for atherosclerosis as we initially expected. This observation is in line with a recent observation published, whilst the present manuscript was in preparation, on an elegant knock-out study in rabbits. Unlike mice and rats, rabbits do express NOX5 physiologically. Here, deleting the Nox5 gene was not only neutral but even aggravated atherosclerosis. Whilst our model has the limitation of only mimicking physiological human expression of Nox5 in endothelial cells, the Nox5 KO rabbit model is based entirely on endogenous expression levels and localization. Thus, our and the rabbit data clearly argue against a general pro-atherosclerotic role of Nox5, despite the earlier observed expression correlation. These data are similar to those by us and others studying Nox4, which is also neutral to protective. We cannot rule out a role for another Nox isoform, e.g., Nox1 or Nox2, but the possibility exists that ROS formation in atherosclerosis is not causal but downstream or an epiphenomenon.

The rather unexpected finding of this study was the clear causal role of endothelial Nox5 in type II abdominal aortic aneurysms under diabetic conditions. This was reminiscent of the role of Nox5 in other atherosclerosis-associated comorbidities, i.e., diabetic kidney disease, hypertension, stroke and myocardial infarction. Indeed, diabetes is a negative risk factor of aortic aneurysms and anti-diabetic treatment regimens afford protection as a function of changes in the vascular extracellular matrix and a more fibrotic phenotype. However, other Nox isoforms cannot be excluded as in human aortic aneurysm, mRNA levels for Nox2 and Nox5 are significantly increased, and expression of potentially protective Nox4 mRNA decreased. Moreover, deletion of Nox1 in mice attenuates angiotensin II-induced aortic aneurysm formation, which may however, differ from the diabetes-dependent mechanism. Obviously, in our study, Nox2 levels in eNOX5ki/ki mice were lower than the diabetic WT mice, yet the difference was not significant. Although unlikely, we cannot exclude that changes in Nox2 expression also play a role in the NOX5-induced aortic aneurysms in diabetes, however, further studies, e.g., focusing on NOX2 protein levels, are needed to support this conclusion. As a limitation of our study, we have not measured the expression of other NOX isoforms including Nox1, therefore, its downstream contribution to the primary effect of NOX5 cannot be ruled out. Furthermore, the pro-inflammatory marker MCP-1 was significantly increased in diabetic mice and was almost double in diabetic ApoE−/− x eNOX5ki/ki mice compared to diabetic ApoE−/− x WT mice, however this increase was not significant.

Downstream of endothelial Nox5, reducing collagen formation may be involved. This would, however, be atypical for Nox5 as, for example, in diabetic kidney disease and human hepatic stellate cells, Nox5 is associated with rather increased extracellular matrix proteins and fibrosis, respectively. Thus, our study has limitations as the downstream mechanisms of Nox5 aggravating diabetic aneurysm remain unclear. Indeed, insoluble form of fibronectin is expressed in endothelial cells and its polymerization into the extracellular matrix is required for the deposition of collagen. This remarkable finding agrees with our results in diabetic mice, where the diabetes-induced overexpression of fibronectin was prevented by knocking in Nox5. Thus, investigation of this effect in vitro, in endothelial cells, is warranted in future studies. Moreover, fibronectin is upregulated in many cancers including non-small cell lung carcinoma (NSCLC) and breast cancer. This suggests that Nox5 may protect against cancer by reducing fibronectin, and that tumor tendency may be lower in eNOX5ki/ki mice. Therefore, future studies of cancers, in particular NSCLC, in Nox5 KO mice expressing Nox5 in endothelial cells and other cell types is warranted.

Despite the effect of Nox5 on fibrotic markers, it had no effect on F4/80 and NOX2 expression between diabetic WT and diabetic eNOX5ki/ki mice. However, there was a tendency for lower expression of both genes in eNOX5ki/ki mice, yet not significant. Thus, there might be a dysfunction of macrophage attraction due to overexpression of Nox5, which is also expressed in macrophages in eNOX5ki/ki mice according to our previous publications, although there was a tendency for an increased MCP-1 expression in the diabetic eNOX5ki/ki group.
As an outlook, it would be of interest to examine the role of Nox5 in other models and types of abdominal aortic aneurysm, e.g., ApoE−/− mice infused with angiotensin II. Rather than the downstream mechanistic consideration, it will be of interest to test Nox5-specific inhibitors for their therapeutic potential once they become available.

Conclusion. The relevance and precise enzymatic source of ROS in atherosclerosis remains unclear. Unlike previous correlations had suggested, endothelial Nox5 is not a relevant source. Instead, Nox5 may be an aggravating or even causal factor in the human diabetic complication of aortic aneurysms, which have a pre-/in-hospital mortality of 40–80%. Given the fact that Nox inhibitors are beginning to be clinically tested our findings may provide a first step towards a mechanism-based, isoform-specific therapy or even prevention of aortic aneurysms.

Figure 4. Endothelial Nox5 expression results in lower vascular collagen accumulation in diabetic eNOX5ki/ki ApoE−/− mice (a). Quantification of trichrome staining in the atherosclerotic plaque and underlying vessel wall of diabetic ApoE−/− mice with (b) and without (c) eNOX5 expression. Assessment of the amount of blue collagen accumulation shows that diabetic animals expressing eNOX5 had significantly less collagen. Data shown as mean ± SEM of n = 6–9 animals/group. Student's t-test between diabetic groups p = 0.012. 50 μm scale bar.
Methods

Animals. Humanized endothelial Nox5 Knock-in (KI) mice were generated and validated as previously described. Briefly, the model was developed using the hypoxanthine phospho-riboisyl-transferase (Hprt) targeted transgenic approach under the control of the Tie2 promoter. Therefore, Nox5 is expressed endogenously mainly in endothelial cells and white blood cells (eNOX5ki/ki) mimicking the physiological expression pattern and levels as in humans. This technology is superior to transgenic animals, e.g., as reported for NOX2 overexpressing mice, where the target gene is randomly inserted and expressed globally in supraphysiological levels. The mice had a mixed genetic background (129/Sv and C57Bl6). Expression of Nox5 in the KI mice tissues was validated by qPCR and compared to Wild Type (WT) mice. Both WT and eNOX5ki/ki mice (56–64 weeks old) (total n = 42) were fed a high cholesterol (Paigen) diet (without cholate) for 28 weeks to induce atherosclerosis. On the day of sacrifice, blood glucose was measured using a glucometer (Contour XT, Ascensia, Switzerland), mice were then anesthetized with 3–4% isoflurane. The abdominal cavity was opened, and blood was withdrawn via a heart puncture. Then, the mouse was flushed with 20 ml nitroprusside and organs were taken out and weighed. The blood collected from the mice was allowed to clot for 30 min to 1 h. After 10 min centrifugation at 10,000 rpm at 4°C, the supernatant (serum) was pipetted and aliquoted in 100μL portions to be stored at −20°C. Cholesterol levels were measured by Cholesterol FS 10 kit (DiaSys–Diagnostic Systems GmbH, Holzheim, Germany). Triglyceride levels were measured by Triglyceride FS 5 EcoLine kit (DiaSys–Diagnostic Systems GmbH, Holzheim, Germany). All aged mice experimental protocols were approved by the Animal Ethics Committee of the Faculty of Health, Medicine and Life Sciences, Maastricht University, Netherlands. All experiments were performed in accordance with the ARRIVE guidelines ("Animal Research: Reporting of In Vivo Experiments"; https://arriveguidelines.org/).

Atherosclerotic plaque area. Assessment of plaque area was undertaken using en face analysis, after staining with Sudan IV-Herxheimer’s solution (BDH, Poole UK) as previously described.

Hematoxylin and Eosin stain. 4μm thick sections of paraffin embedded aortic arches and valvular heart region, were cut and stained with Hematoxylin and Eosin to detect fatty streaks and/or plaques in the aortic arch and valvular heart region.

Quantitative RT-PCR. Total RNA was extracted after homogenising whole aorta (Polytron PT-MR2100; Kinematica, Littau/Lucerne, Switzerland) in TRIzol reagent (Invitrogen Australia, Mt Waverley, Vic, Australia) before embedding in paraffin, or snap frozen in liquid nitrogen for RT-PCR.

Immunohistochemical and trichrome staining. Immunohistochemical and trichrome staining was performed on 4μm paraffin embedded sections as described previously. Rabbit anti-fibronectin (1:1000, Dako#A024502-2, ELTech Group, Braeside, Vic, Australia), rabbit anti-monocyte chemoattractant protein-1 (MCP-1; #ab7202, Abcam, Cambridge, MA, USA), rabbit anti-nitrotyrosine (1:200, Chemicon #ab411, Merck, Darmstadt, Germany), rabbit anti-vascular cell adhesion molecule-1 (VCAM-1; 1:50, #ab134047, Abcam). Photoradiographs and analysis for percentage collagen staining in the plaque and wall immediately adjacent to the plaque (exclusive of adventia) was conducted as described previously. Nissl (Nikon Eclipse Ci microscope (Nikon, Tokyo, Japan) with a DS-Fi3 digital camera (Nikon, Tokyo, Japan) using Nikon NIS Elements software (Nikon); ver. 7.0, MediaCybernetics for percentage area of blue staining assessed in RGB). Note one data point represents the average of all sections present from one animal. Non-diabetic animals have significantly less plaque than diabetic mice; Fig. 4 represents the average collagen content of 2 or more plaques per animal.
Statistical analysis. Data were analyzed for normality using the D'Agostino-Pearson test before being analyzed. T-test was used to compare between two groups and one or two-way ANOVA followed by Tukey's multiple comparisons test to compare between more than two groups. \( P<0.05 \) was considered significant. Results are expressed as mean ± SEM. Data were analyzed using Prism GraphPad software.

Data availability

All data needed to evaluate the conclusions in the paper are present in the paper or the Supplementary Materials.

Received: 16 March 2022; Accepted: 28 June 2022
Published online: 07 July 2022

References

1. Libby, P. The biology of atherosclerosis comes full circle: Lessons for conquering cardiovascular disease. Nat. Rev. Cardiol. 18, 683–684 (2021).
2. Libby, P. et al. Atherosclerosis. Nat. Rev. Dis. Prim. 5, 56 (2019).
3. Golledge, J. & Norman, P. E. Atherosclerosis and abdominal aortic aneurysm: Cause, response, or common risk factors?. Arterioscler. Thromb. Vasc. Biol. 30, 1075–1077 (2010).
4. Peshkova, I. O., Schaefer, G. & Koltsosva, E. K. Atherosclerosis and aortic aneurysm - is inflammation a common denominator?. FEBS J. 283, 1636–1652 (2016).
5. Kattoo, A. J., Pothineni, N. V. K., Palagiri, D. & Mehta, J. L. Oxidative stress in atherosclerosis. Curr. Atheroscler. Rep. 19, 42 (2017).
6. Gusk, B. et al. Mechanisms of oxidative stress in human aortic aneurysms — Association with clinical risk factors for atherosclerosis and disease severity. Int. J. Cardiol. 168, 2389–2396 (2013).
7. Miller, F. J. Jr. et al. Oxidative stress in human abdominal aortic aneurysms: A potential mediator of aneurysmal remodeling. Arterioscler. Thromb. Vasc. Biol. 22, 560–565 (2002).
8. Casas, A. I. et al. On the clinical pharmacology of reactive oxygen species. Pharmacol. Rev. 72, 801–828 (2020).
9. Schmidt, H. H. H., Ghezzi, P. & Cuadrado, A. Reactive Oxygen Species: Network Pharmacology and Therapeutic Applications (Springer, Cham, 2021).
10. Gray, S. P. et al. NADPH oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosis. Circulation 127, 1888–1902 (2013).
11. Sheehan, A. L. et al. Role for Nox1 NADPH oxidase in atherosclerosis. Atherosclerosis 216, 321–326 (2011).
12. Gavazzi, G. et al. Nox1 deficiency protects from aortic dissection in response to angiotensin II. Hypertension 50, 189–196 (2007).
13. Yin, C. et al. Genome-wide association study identifies loci and candidate genes for non-idiopathic pulmonary hypertension in Eastern Chinese Han population. BMC Pulm. Med. 18, 1–8 (2018).
14. Gray, S. P. et al. Reactive oxygen species can provide atheroprotection via Nox4-dependent inhibition of inflammation and vascular remodeling. Arterioscler. Thromb. Vasc. Biol. 36, 295–307 (2016).
15. Schürmann, C. et al. The NADPH oxidase Nox4 has anti-atherosclerotic functions. Eur. Heart J. 36, 3447–3456 (2015).
16. Gusk, T. J. et al. Calcium-dependent Nox5 nicotinamide adenine dinucleotide phosphate oxidase contributes to vascular oxidative stress in human coronary artery disease. J. Am. Coll. Cardiol. 52, 1803–1809 (2008).
17. Elbatreek, M. H. et al. Nox5-induced uncoupling of endothelial NO synthase is a causal mechanism and theragnostic target of an age-related hypertension endothyte. PLoS Biol. 18, e3000885 (2020).
18. Casas, A. I. et al. Calcium-dependent blood-brain barrier breakdown by Nox5 limits postreperfusion benefit in stroke. J. Clin. Invest. 130, 1772–1778 (2019).
19. Gusev, G. S. & Reardon, C. A. Diet and murine atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 26, 242–249 (2006).
20. Li, Y., Gilbert, T. R., Matsumoto, A. H. & Shi, W. Effect of aging on fatty streak formation in a diet-induced mouse model of atherosclerosis. J. Vasc. Res. 45, 205–210 (2008).
21. Jawien, J. Mouse models of experimental atherosclerosis as a tool for checking a putative anti-atherogenic action of drugs. Atherosclerosis. Hypothesis https://doi.org/10.10722/260701 (2012).
22. Emini Veseli, B. et al. Animal models of atherosclerosis. Eur. J. Pharmacol. 816, 3–13 (2017).
23. Holterman, C. et al. Nephropathy and elevated BP in mice with podocyte-specific NADPH oxidase 5 expression. J. Am. Soc. Nephrol. 25, 784–797 (2014).
24. Iha, J. et al. NADPH oxidase Nox5 accelerates renal injury in diabetic nephropathy. Diabetes 66, 2691–2703 (2017).
25. Daugheyth, A., Manning, M. W. & Cassis, L. A. Antagonism of AT2 receptors augments angiotensin II-induced abdominal aortic aneurysms and atherosclerosis. Br. J. Pharmacol. 134, 865–870 (2001).
26. Xiong, W. et al. Inhibition of reactive oxygen species attenuates aneurysm formation in a murine model. Atherosclerosis 202, 128–134 (2009).
27. BeAlba, R. S. et al. Nox5 variants are functionally active in endothelial cells. Free Radic. Biol. Med. 42, 446–459 (2007).
28. Zhang, Q. et al. Paradoxical activation of endothelial nitric oxide synthase by NADPH oxidase. Arterioscler. Thromb. Vasc. Biol. 28, 1627–1633 (2008).
29. Pethoe, G. L. et al. Disruption of the NADPH oxidase 5 Gene aggravates atherosclerosis in rabbits. Circ. Res. https://doi.org/10.1161/CIRCRESAHA.120.318611 (2021).
30. Iha, J. C. et al. Endothelial or vascular smooth muscle cell-specific expression of human Nox5 exacerbates renal inflammation, fibrosis and albuminuria in the Akita mouse. Diabetologia 62, 1712–1726 (2019).
31. Hahn, N. et al. Nox5 expression is increased in intramyocardial blood vessels and cardiomyocytes after acute myocardial infarction in humans. Am. J. Pathol. 180, 2222–2229 (2012).
32. Patel, K., Zafar, M. A., Ziganshin, B. A. & Elefteriades, J. A. Diabetes mellitus: Is it protective against aneurysm? A narrative review. Cardiology 141, 107–122 (2018).
33. Torsney, E., Pirianov, G. & Cockrell, G. W. Diabetes as a negative risk factor for abdominal aortic aneurysm — does the disease aetiology or the treatment provide the mechanism of protection? Curr. Vasc. Pharmacol. 11, 293–298 (2013).
34. Raffot, J. et al. Diabetes and aortic aneurysm: Current state of the art. Cardiovasc. Res. 114, 1702–1713 (2018).
35. Thomas, M. et al. Deletion of p47phox attenuates angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-deficient mice. Circulation 114, 404–413 (2006).
36. Andueza, A. et al. NADPH oxidase 5 promotes proliferation and fibrosis in human hepatic stellate cells. Free Radic. Biol. Med. 126, 15–26 (2018).
37. Jaffe, E. A. & Mosher, D. F. Synthesis of fibrinogen by cultured human endothelial cells. J. Exp. Med. 147, 1779–1791 (1978).
38. Sottile, J. & Hocking, D. C. Fibrinogen polymerization regulates the composition and stability of extracellular matrix fibrils and cell-matrix adhesions. Mol. Biol. Cell 13, 3546–3559 (2002).
39. Sottile, J. et al. Fibrinogen-dependent collagen I deposition modulates the cell response to fibrinogen. Am. J. Physiol. Cell Physiol. 293, C1934–C1946 (2007).
40. Han, J. Y. et al. Immunohistochemical expression of integrins and extracellular matrix proteins in non-small cell lung cancer: Correlation with lymph node metastasis. Lung Cancer 41, 65–70 (2003).
41. Jakowlew, S. B., Mariano, J. M., You, L. & Mathias, A. Differential regulation of protease and extracellular matrix protein expression by transforming growth factor-beta 1 in non-small cell lung cancer cells and normal human bronchial epithelial cells. Biochim. Biophys. Acta 1353, 157–170 (1997).
42. Cao, R. Y., Amand, T., Ford, M. D., Piomelli, U. & Funk, C. D. The Murine angiotensin II-induced abdominal aortic aneurysm model: Rupture risk and inflammatory progression patterns. Front. Pharmacol. 1, 9 (2010).
43. Dao, V. T. V. et al. Nitric oxide synthase inhibitors into the clinic at last. Handb. Exp. Pharmacol. 264, 169–204 (2021).
44. Elbatreek, M. H., Mucke, H. & Schmidt, H. H. H. W. NOX inhibitors: From bench to naxibs to bedside. Handb. Exp. Pharmacol. 264, 145–168 (2021).
45. Douglas, G. et al. Endothelial-specific Nox2 overexpression increases vascular superoxide and macrophage recruitment in ApoE−/− mice. Cardiovasc. Res. 94, 20–29 (2012).
46. Douglas, G., Bendall, J. K. & Channon, K. M. Endothelial-specific Nox2 over-expression increases vascular superoxide production but does not alter atherosclerotic plaque or AngII-dependent aneurysm formation. Atherosclerosis 213, e12–e13 (2010).
47. Bendall, J. K. et al. Endothelial Nox2 overexpression potentiates vascular oxidative stress and hemodynamic response to angiotensin II. Studies in endothelial-targeted Nox2 transgenic mice. Circ. Res. 100, 1016–1025 (2007).
48. Watson, A. M. D. et al. The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice. Diabetologia 53, 192–203 (2010).
49. Candido, R. et al. Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis. Circulation 109, 1536–1542 (2004).

Acknowledgements
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 777111 (REPO-TRIAL). This reflects only the author’s view and the European Commission is not responsible for any use that may be made of the information it contains. This work was also supported by the National Health and Medical Research Council (NHMRC) with a Senior Research Fellowships and Project Grant to KAMJ-D (APP 1059124 and APP 1163233), and a Project Grant to AMDW (GNT1079645). We would like to thank Ms. Megan Haillay, Ms. Elisha Lastavec, and Ms. Dilian Karagoz for their excellent technical assistance.

Author contributions
K.A.M.J.D. and H.H.H.W.S. designed the research; F.H., A.M.D.W., M.H.E., P.W.M.K., W.K., K.C.S., A.D., and J.J. performed research; F.H., A.M.D.W., M.H.E., and P.W.M.K. analyzed data; and F.H., A.M.D.W., M.H.E., H.H.H.W.S., and K.A.M.J.D. wrote the paper.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-022-15706-5.
Correspondence and requests for materials should be addressed to M.H.E., H.H.H.W.S. or K.A.M.J.-D.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022